Energy Regulation Mechanism and Therapeutic Potential of Asprosin
Open accessThe DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Genetic studies of patients with neonatal progeroid syndrome led to the discovery of the novel fasting-induced, glucogenic, and orexigenic hormone named asprosin, the C-terminal cleavage product of profibrillin. Upon secretion, asprosin travels to the liver, where it exerts a glucogenic effect through OR4M1, an olfactory G-protein–coupled receptor. It also crosses the blood-brain barrier to stimulate appetite-modulating neurons in the arcuate nucleus of the hypothalamus, exerting an orexigenic effect via an as yet unidentified receptor. Specifically, it stimulates appetite by activating orexigenic AgRP neurons and inhibiting anorexigenic POMC neurons. Studies have also focused on the therapeutic potential of inhibiting asprosin for treatment of obesity and type 2 diabetes, both of which are characterized by high levels of circulating asprosin. It has been shown that anti-asprosin monoclonal antibodies reduce blood glucose, appetite, and body weight, validating asprosin as a therapeutic target. Current work aims to uncover key features of the asprosin biology such as the identification of its neuronal receptor, identification of the secretion mechanism from adipose tissue, and development of anti-asprosin monoclonal antibodies as diabetes and obesity therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Anti-asprosin monoclonal antibodies reduce blood glucose, appetite, and body weight [183].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [183]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A role for ghrelin in the central regulation of feeding
Nakazato, M., Murakami, N., Date, Y., Kojima, M., Matsuo, H., Kangawa, K., & Matsukura, S. (2001) · Nature · doi:10.1038/35051587 · Cited by 3,443 · cited 1×
“Interestingly, it took several hours after injection before the increase in food intake occurred, differentiating asprosin from the acutely acting hormone ghrelin (26).”
BackgroundThe role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review
Klok, M. D., Jakobsdottir, S., & Drent, M. L. (2007) · Obesity Reviews · doi:10.1111/j.1467-789x.2006.00270.x · Cited by 1,442 · cited 1×
“Leptin, an anorexigenic hormone secreted from white adipose tissue, also regulates energy balance through modulation of AgRP and POMC neurons (27).”
BackgroundMechanisms of insulin resistance in obesity
Ye, J. (2013) · Frontiers of Medicine · doi:10.1007/s11684-013-0262-6 · Cited by 699 · cited 1×
“Additionally, the vast majority of patients with obesity also manifest with insulin resistance (35).”
BackgroundAsprosin, a Fasting-Induced Glucogenic Protein Hormone
Romere, C., Duerrschmid, C., Bournat, J., Constable, P., Jain, M., Xia, F., Saha, P. K., Del Solar, M., Zhu, B., York, B., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.063 · Cited by 591 · cited 10×
“While FBN1 is expressed in many tissues, its highest expression in both humans and mice is inwhite adipose (1).”
BackgroundSelf-citationAsprosin is a centrally acting orexigenic hormone
Duerrschmid, C., He, Y., Wang, C., Li, C., Bournat, J. C., Romere, C., Saha, P. K., Lee, M. E., Phillips, K. J., Jain, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4432 · Cited by 357 · cited 10×
“Fbn1 mice were created using CRISPR/ Cas9 to induce a frame shift leading to the deletion of the asprosin-coding region (9).”
BackgroundMethodSelf-citationCell type-specific transcriptomics of hypothalamic energy-sensing neuron responses to weight-loss
Henry, F. E., Sugino, K., Tozer, A., Branco, T., & Sternson, S. M. (2015) · eLife · doi:10.7554/elife.09800 · Cited by 240 · cited 1×
“Comprehensive gene expression profiles did not show Olfr734 expression in AgRP or POMC neurons in mice in either the fasted or fed state (25).”
BackgroundOLFR734 Mediates Glucose Metabolism as a Receptor of Asprosin
Li, E., Shan, H., Chen, L., Long, A., Zhang, Y., Liu, Y., Jia, L., Wei, F., Han, J., Li, T., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.05.022 · Cited by 221 · cited 20×
“They also had reduced cAMP levels, decreased hepatic glucose release, and improved insulin sensitivity (as measured by insulin tolerance test, hyperinsulimic-euglycemic clamp, and glucose tolerance test) compared with wild-type mice (22).”
BackgroundMethodResultInfluentialWang, Y., Qu, H., Xiong, X., Qiu, Y., Liao, Y., Chen, Y., Zheng, Y., & Zheng, H. (2018) · Mediators of Inflammation · doi:10.1155/2018/9471583 · Cited by 189 · cited 3×
“The authors also showed that plasma asprosin concentration is positively correlated with patient waist circumference, fasting plasma glucose, HbA1c, triglycerides, impaired glucose regulation, type 2 diabetes, and HOMA for insulin resistance (19).”
BackgroundInfluentialLee, T., Yun, S., Jeong, J. H., & Jung, T. W. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.03.001 · Cited by 188 · cited 1×
“(16) found that MIN6 pancreatic b-cells and human primary islets containing b-cells secrete asprosin and that secretion is induced by palmitate in a dosedependent manner.”
BackgroundZhang, L., Chen, C., Zhou, N., Fu, Y., & Cheng, X. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2017.10.034 · Cited by 182 · cited 3×
“While serum asprosin was positively associated with adiposity-related parameters such as BMI, waist circumference, and waist-to-hip ratio in patients with type 2 diabetes, these adiposity markers were not independently associated with asprosin concentrations (18).”
BackgroundInfluential
Cited by
Mazur-Biały, A. I. (2021) · Nutrients · doi:10.3390/nu13020620 · Cited by 101
“Olfr734 is a mouse ortholog of human OR4M1 r ceptor [8].”
BackgroundInfluentialBays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
Old Paradoxes and New Opportunities for Appetite Control in Obesity
Montégut, L., López-Otín, C., Magnan, C., & Kroemer, G. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.02.005 · Cited by 48
Discovery of a possible role of asprosin in ovarian follicular function
Maylem, E. R. S., SPICER, L. J., Batalha, I. M., & Schütz, L. F. (2020) · Journal of Molecular Endocrinology · doi:10.1530/jme-20-0218 · Cited by 51
A Serum Marker for Early Pancreatic Cancer With a Possible Link to Diabetes
Nam, H., Hong, S., Jung, K. H., Kang, S., Park, M. S., Kang, S., Kim, H. S., Mai, V.-H., Kim, J., Lee, H., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab191 · Cited by 38
Xu, Y., Zhu, H., Li, W., Chen, D., Xu, Y., Xu, A., & Ye, D. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108284 · Cited by 31
A state of the art review on the novel mediator asprosin in the metabolic syndrome
Luís, C., Fernandes, R., Soares, R. A., & HAFE, P. V. (2020) · Porto Biomedical Journal · doi:10.1097/j.pbj.0000000000000108 · Cited by 37
“Research already recognized that anti-asprosin monoclonal antibodies can reduce blood glucose, decrease appetite therefore body weight and could be considered as a diabetic and obesogenic therapy.(37)”
BackgroundFibrillin-1 and asprosin, novel players in metabolic syndrome
SUMMERS, K. M., Bush, S. J., Davis, M. R., Hume, D. A., Keshvari, S., & West, J. A. (2022) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2022.106979 · Cited by 32
Ulloque‐Badaracco, J. R., Al‐kassab‐Córdova, A., Hernández-Bustamante, E. A., Alarcón‐Braga, E. A., Robles-Valcárcel, P., Huayta-Cortez, M. A., Guzmán, J. C. C., Seminario-Amez, R. A., & Benites-Zapata, V. A. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103095 · Cited by 25
Quercetin targets VCAM1 to prevent diabetic cerebrovascular endothelial cell injury
Huang, J., Lin, W., Sun, Y., Wang, Q., He, S., Han, Z., Lu, L., Kang, X., Chen, Y., Guo, H., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.944195 · Cited by 25
“Various pathways are involved in these processes, including the production of reactive oxygen species, mitochondrial dysfunction and upregulation of vasoconstrictor endothelin-1 as well as MMP-9 expressions (Bhatti et al., 2017; Hougaard et al., 2020; Urner et al., 2020; D’Onofrio et al., 2021).”
BackgroundAsprosin is associated with anorexia and body fat mass in cancer patients
Du, C., Wang, C., Guan, X., Li, J., Du, X., Xu, Z., Li, B., Liu, Y., Fu, F., Huo, H., et al. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05621-8 · Cited by 27
“Third, we did not include factors that can influence asprosin levels into this study, such as physical activity, circadian, and asprosin catabolism [8, 17, 22, 33].”
BackgroundÇantay, H., Binnetoğlu, K., Gül, H. F., & BİNGÖL, S. A. (2022) · Obesity · doi:10.1002/oby.23471 · Cited by 23
“Several studies have indicated that asprosin, known to cross the blood-brain barrier, uses the cAMP-protein kinase A pathway to activate Agoutirelated protein neurons, to suppress proopiomelanocortin neurons, and, ultimately, to cause an increase in food intake [21].”
BackgroundPérez-López, F. R., López-Baena, M. T., Pérez‐Roncero, G. R., Chedraui, P. A., Varikasuvu, S. R., & García-Alfaro, P. (2022) · Gynecological Endocrinology · doi:10.1080/09513590.2022.2152790 · Cited by 22
“The pharmacological inhibition of asprosin to manage excessive body weight and insulin resistance might open a new therapeutic avenue since anti-asprosin antibodies may reduce appetite, body weight, and circulating glucose levels [36].”
BackgroundGe, R., Chen, J.-L., Zheng, F., Yin, S., Dai, M., Wang, Y.-M., Chen, Q., Li, Y.-H., Zhu, G.-Q., & Chen, A.-D. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e31659 · Cited by 20
“Inhibition of asprosin production attenuates hyperinsulinism in the mice with diet-induced obesity [24 – 26].”
Dai, C., & Zhu, W. (2022) · Medicine · doi:10.1097/md.0000000000031334 · Cited by 18
“[20] In contrast, asprosin crosses the blood-brain barrier and activates pro-appetitive AgRP neurons, and inhibits anorexic POMC neurons via the G protein-cAMP-PKA pathway.[21] Liraglutide may antagonize the neuronal activity of asprosin, thereby suppressing appetite and reducing body weight.”
BackgroundSuder, A., Makiel, K., Targosz, A., Kosowski, P., & Malina, R. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-79853-7 · Cited by 17
The effect of thyroid dysfunction and treatment on adropin, asprosin and preptin levels in rats
Moğulkoç, R., Dasdelen, D., Baltacı, S. B., Baltacı, A. K., & Sivrikaya, A. (2020) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2020-0058 · Cited by 17
Xu, L., Cui, J., Li, M., Wu, Q., Liu, M., Xu, M., Shi, G., Yin, J., & Yang, J. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s361808 · Cited by 18
Lv, D., Wang, Z., Meng, C., Li, Y., & Ji, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-62124-w · Cited by 16
Serum asprosin levels are associated with obesity and insulin resistance in Arab adults
Al‐Daghri, N. M., Alokeel, R. M. I., Alamro, A. A., Ansari, M. G. A., Hussain, S. D., Amer, O. E., Yakout, S. M., Alnaami, A. M., & Sabico, S. (2021) · Journal of King Saud University - Science · doi:10.1016/j.jksus.2021.101690 · Cited by 18
Zhou, J., Yuan, W., Guo, Y., Wang, Y., Dai, Y., Shen, Y., & Liu, X. (2023) · Renal Failure · doi:10.1080/0886022x.2023.2220425 · Cited by 12
Asprosin contributes to vascular remodeling in hypertensive rats via superoxide signaling
Xu, Z.-Q., Li, X., Zhu, R., Ge, R., Wei, H., Shi, H., Wang, Z., Yang, C., Yang, Y., Lu, X.-J., et al. (2024) · Journal of Hypertension · doi:10.1097/hjh.0000000000003751 · Cited by 9
Adipokines and their role in acute pancreatitis
Rafaqat, S., Vujacic, I. R., Patoulias, D., Khurshid, H., & Klisic, A. N. (2024) · Journal of Medical Biochemistry · doi:10.5937/jomb0-47515 · Cited by 10
“It was recently shown that anti-asprosin monoclonal antibodies lead to decreased appetite, lowering blood glucose, and body weight loss and future researches are needed to enlighten asprosins’ signaling pathways and its receptors (84).”
BackgroundCrucial roles of asprosin in cisplatin-induced ferroptosis and acute kidney injury
Zheng, F., Lei, J., Wang, J.-X., Xu, X., Zhou, B. R., Ge, R., Dai, M., Dong, H.-K., Wu, N., Li, Y.-H., et al. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.12.024 · Cited by 10
Ma, L., Wang, Z., Li, S., Li, M., Wu, Q., Liu, M., Xu, M., Shi, G., Yin, J., Wang, Y., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14313 · Cited by 8
Gonacin: A germ cell-derived hormone with glucogenic, orexigenic, and gonadal activities
Hu, Y., Zhao, S., Liu, Z., Kang, T., Hsueh, A. J. W., & Li, J. (2023) · iScience · doi:10.1016/j.isci.2023.108065 · Cited by 7
“6,8 In addition, human FBN2 encodes a placenta-secreted glucogenic hormone placensin 9 , capable of regulating metabolic and placental functions.”
BackgroundChemerin and Asprosin as Promising Biomarkers of Metabolic Syndrome: A Scoping Review
Ozyalcin, B., & Şanlıer, N. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00665-5 · Cited by 6
“3c) [40, 42].”
Asprosin as a regulator of hepatic lipogenesis and its association with hepatic steatosis
Acevedo-Carabantes, J. A., Vázquez, S., Noriega, L. G., Guevara‐Cruz, M., Velázquez‐Villegas, L. A., Sánchez‐Tapia, M., Uscanga, L. F., Torres, N., & Tovar, A. R. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100921 · Cited by 7
“Asprosin, a hormone predominantly secreted by adipose tissue, has emerged as a significant player in the complex network of metabolic regulation (32, 33) with particular influence on hepatic metabolism (20, 22).”
Wang, Y., Liu, W., Liu, C., Zhou, Z., Chen, S., Huang, Q., Wang, L., Zeng, G., & Huang, Q. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.01006.2024 · Cited by 6
Maylem, E. R. S., Schütz, L. F., & SPICER, L. J. (2024) · Reproduction Fertility and Development · doi:10.1071/rd24027 · Cited by 7
Ristić, J., KODALAK, S., Peralta-Jiménez, G. A., de Lima, M. M., Kovačević, M., Mašić, S., & Nikolić, T. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s527579 · Cited by 5
“51 Additionally, asprosin crosses the blood-brain barrier to influence the hypothalamus, stimulating appetite by activating AgRP neurons and suppressing POMC neurons.”
Alsaif, M., Field, C. J., Colin-Ramírez, E., Prado, C. M. M., & Haqq, A. M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082268 · Cited by 5
“Two studies have reported higher levels of asprosin in children with obesity compared to children with normal weight [12], while Long et al.”
BackgroundInfluentialEvaluation of Asprosin Hormone in Hypothyroidism Patients
Ateah, N., Y.Abed, A., & Abed, B. A. (2023) · Ibn AL- Haitham Journal For Pure and Applied Science · doi:10.30526/36.2.3008 · Cited by 5
THE GENDER FACTOR EFFECT FOR THE EDOCRYNE FUNCTION OF MESENCHYMAL TISSUES IN CHILDREN AND ADOLESCENT
Shestopalov, A. V., Davydov, V. V., Tumanyan, G. T., Savchuk, D. V., Teplyakova, E. D., Shin, V. F., Grigorieva, T. V., Laikov, A. V., Borisenko, O. V., & Roumiantsev, S. A. (2023) · Molekulyarnaya Meditsina (Molecular medicine) · doi:10.29296/24999490-2023-02-08 · Cited by 3
Sulaiman, D. M. (2021) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20213067 · Cited by 3
Evaluation of Serum Asprosin Levels in Patients with T2DM in Duhok District, Iraqi Kurdistan Region
Taha, R., & Sulaiman, D. M. (2022) · Journal of Life and Bio Sciences Research · doi:10.38094/jlbsr30273 · Cited by 3
“In addition to this, asprosin is one of the molecules that play a role in facilitating the release of sugar from the hepatocytes, which ultimately leads toward hyperglycemia (Hoffmann et al., 2020).”
BackgroundReview of Asprosin as new Biomarker for diagnosis different Diseases
Atta, S. E., Abed, B. A., Salman, I. N., & Ghannawi, L. A. (2023) · University of Thi-Qar Journal of Science · doi:10.32792/utq/utjsci/v10i2.1125 · Cited by 2
Jiang, J., He, J., Song, X.-Y., Liu, M., Kang, X., Wang, B., Zhang, P., Zou, W., & Tang, X. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115931 · Cited by 2
Abdulwahid, W. N., & Obaid, R. M. (2026) · Baghdad Science Journal · doi:10.21123/2411-7986.5349 · Cited by 1
Mahmmoed, B. J., Hilal, N. N., & Sarhat, E. R. (2023) · South Asian Research Journal of Pharmaceutical Sciences · doi:10.36346/sarjps.2023.v05i04.011 · Cited by 1
Asprosin in nonalcoholic fatty liver disease and hypothyroidism: a case-control study
Aboul-Seoud, M. A.-L., Ghitany, M. K., Sharaki, O. A., Abdul-Aziz, A. A., & Shater, M. S. S. (2024) · Alexandria Journal of Medicine · doi:10.1080/20905068.2024.2381153 · Cited by 1
“It also inhibits the proopiomelanocortin (POMC) appetite-suppressing neurons [8].”
Ghalavand, A., Nasiri, M., Kardan, H., Azari, B. B., Delaramnasab, M., & Dadvar, N. (2024) · International journal of basic science in medicine · doi:10.34172/ijbsm.36628 · Cited by 1
“11 Asprosin plays an important role in regulating glucose homeostasis and lipid metabolism through the cyclic adenosine monophosphate-protein kinase A pathway in the liver and hypothalamus.”
BackgroundTrojanowska, P., Trojanowska, A., Szydełko, J., Tywanek, E., & Łuczyk, R. J. (2020) · Journal of Education Health and Sport · doi:10.12775/jehs.2020.10.09.102
Transglutaminase mediated asprosin oligomerization allows its tissue storage as fibersPreprint
Morcos, Y. A. T., Pryymachuk, G., Lütke, S., Gerken, A., Godwin, A. R. F., Jowitt, T. A., Piekarek, N., Hoffmann, T., Niehoff, A., Odenthal, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.04.474899
“Surface plasmon resonance SPR experiments were performed as described previously (10, 13) using a BIAcore 2000 system (BIAcore AB, Uppsala, Sweden).”
BackgroundMethodInfluentialKhalil, S., El-Fatah, S. S. A., Fathy, M., Elwany, N. E., Ahmad, E. A., Mohamed, N. M., & Habib, M. A. (2023) · Zagazig University Medical Journal · doi:10.21608/zumj.2023.209146.2796
Yardım, M. (2024) · International journal of medical biochemistry/International journal of medical biochemistry : · doi:10.14744/ijmb.2024.55376 · Cited by 1
“The fact that asprosin ameliorates cardiac endothelial damage and corrects dilated cardiomyopathy in diabetic mice supports its cardioprotective nature [20–22].”
BackgroundResearch Progress on Inflammatory Adipocytokines in Polycystic Ovary Syndrome
薛, 艳. (2025) · Medical Diagnosis · doi:10.12677/md.2025.152022
Erdoğan, E., & Yetişgen, A. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-12227-0
“Given its involvement in both inflammatory pathways and energy metabolism, asprosin may serve as a mediator at the intersection of metabolic and immune dysregulation [18].”
Xi, Y.-J., Cai, R., Hu, S.-W., Zhang, B., Xu, H., Zhao, H.-Y., Yang, H.-J., & Guo, F.-F. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.157926
Metabolic Roles of Acyl Coenzyme A-Binding Protein (ACBP)/Diazepam Binding Inhibitor (DBI)
Joseph, A. (2021) · theses.fr (ABES) · doi:10.70675/b045685ezd444z4b46zb0f9z0e726ceac466
Ovalı, M. A., Öztopuz, Ö., Karaboğa, İ., Şehitoğlu, M. H., Demir, U., & UZUN, M. (2026) · Archives of Medical Research · doi:10.1016/j.arcmed.2026.103439
Bulu, G., Akyol, A., Kuloğlu, T., Bulu, A., & Şanlı, C. (2026) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/ceog52123
Chen, J., Zhou, F., Sun, X., Li, Z., Sun, S., Zhang, Y., & Wan, L. (2026) · PeerJ · doi:10.7717/peerj.21577
“Among them, the activation of POMC neurons usually inhibits appetite, while the activation of NYP/AgRP neurons promotes appetite ( Hoffmann, Xie & Chopra, 2020 ; Mazur-Bialy, 2021 ).”
Bozok, Ü. G., Böyük, G., Bayraktar, B., & Kotan, G. C. (2026) · Turkish Journal of Agriculture - Food Science and Technology · doi:10.24925/turjaf.v14i9.2562-2568.9088
Linking Digital Addiction to Mindful Eating: The Mediating Role of Neuroendocrine Biomarkers
Esgin, Ö., & Bayraktar, B. (2026) · Nutrition · doi:10.1016/j.nut.2026.113471
Uzanulu, M. F., Ak, M., Bolat, L., Yigit, O. S., Uçar, C., ÇİTİL, H. M., & Seyhan, H. K. (2026) · Diagnostics · doi:10.3390/diagnostics16213700
Metadata
- Authors
- Hoffmann, J. G., Xie, W., & Chopra, A. R.
- Affiliations
- University Hospitals of Cleveland (US)
- Corresponding author
- Chopra, Atul R.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2020-03-16
- Volume
- 69
- Issue
- 4
- Pages
- 559-566
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC7085243
- OpenAlex
- W3011199148
- Cited by
- 52
- References
- 41
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 12 · 2023: 7 · 2022: 11 · 2021: 6 · 2020: 5
- FWCI
- 0.98
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- asprosin, blood-brain barrier, hypothalamic regulation of appetite, arcuate nucleus, AgRP neurons, POMC neurons, obesity, type 2 diabetes, adipose tissue secretion, energy regulation
- MeSH terms
- Fibrillin-1, Animals, Blood Glucose, Diabetes Mellitus, Type 2, Energy Metabolism, Humans, Microfilament Proteins, Obesity, Peptide Fragments, Peptide Hormones, Adipokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.